{"entity":{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","aka":[],"tldr":"Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.","summary":"Andrea Sartore-Bianchi is a medical oncologist at the Niguarda Cancer Center in Milan. He was first author of the 2016 Lancet Oncology report of HERACLES, the phase 2 trial in which trastuzumab plus lapatinib produced responses in about a third of patients with heavily pretreated HER2-amplified, KRAS wild-type metastatic colorectal cancer, establishing HER2 as a target in the disease. His research covers resistance to anti-EGFR antibodies and molecular selection for therapy.","asOf":"2026-09-18","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["her2-amplified-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["niguarda-cancer-center"],"pathways":[],"terms":[],"trials":["heracles"],"people":[],"bottlenecks":[],"keyPapers":["paper-heracles-lancet-oncol-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Niguarda Cancer Center and University of Milan","institutionId":"niguarda-cancer-center","specialisms":["HER2-amplified colorectal cancer","Precision oncology","Anti-EGFR therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartore-Bianchi%5BAuthor%5D"}],"papers":[],"orcid":"0000-0003-0780-0409"},"route":"/people/andrea-sartore-bianchi/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"}],"institution":[{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","route":"/institutions/niguarda-cancer-center/"}],"trial":[{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/"}],"paper":[{"id":"paper-heracles-lancet-oncol-2016","kind":"paper","name":"HERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer","route":"/key-papers/paper-heracles-lancet-oncol-2016/"}]}}